Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2026)

Aurinia Pharmaceuticals has reported Income from Continuing Operations for 8 years, with the latest figure at 34355000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 47.14% year-over-year to 34355000.0; the trailing twelve-month figure through Mar 2026 stood at 298168000.0 (up 648.13% YoY), and the FY2025 full-year result was 287157000.0, up 4892.3% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 34355000.0, down from 210749000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 210749000.0 in Q4 2025, with the low at 37630000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 8298117.65 across 5 years, with a median of 8989000.0 in 2022.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 49.59% — and 2025, when it surged 14168.72%.
• Aurinia Pharmaceuticals' Income from Continuing Operations stood at 26018000.0 in 2022, then retreated by 3.26% to 26867000.0 in 2023, then jumped by 105.5% to 1477000.0 in 2024, then surged by 14168.72% to 210749000.0 in 2025, then slumped by 83.7% to 34355000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 34355000.0 (Q1 2026), 210749000.0 (Q4 2025), and 31551000.0 (Q3 2025), per Business Quant data.